pioglitazone has been researched along with Cerebrovascular Disorders in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to conduct a direct comparison of TZDs (pioglitazone and rosiglitazone) and their relationship to cardiovascular events (myocardial infarction [MI], angina, congestive heart failure [CHF], and cerebral vascular accident [CVA]) in Taiwanese patients with type 2 diabetes mellitus (DM)." | 3.77 | Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. ( Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC, 2011) |
| "Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance." | 1.46 | Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. ( Badhwar, A; Brown, R; Hamel, E; Haqqani, AS; Stanimirovic, DB, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KC | 1 |
| Learman, CR | 1 |
| Baker, GB | 1 |
| Weaver, CL | 1 |
| Chung, PS | 1 |
| Kim, HG | 1 |
| Song, MS | 1 |
| Katsiki, N | 1 |
| Mikhailidis, DP | 1 |
| Inzucchi, SE | 1 |
| Viscoli, CM | 1 |
| Young, LH | 1 |
| Furie, KL | 1 |
| Gorman, M | 1 |
| Lovejoy, AM | 1 |
| Dagogo-Jack, S | 1 |
| Ismail-Beigi, F | 1 |
| Korytkowski, MT | 1 |
| Pratley, RE | 1 |
| Schwartz, GG | 1 |
| Kernan, WN | 1 |
| Pantoni, L | 1 |
| Badhwar, A | 1 |
| Brown, R | 1 |
| Stanimirovic, DB | 1 |
| Haqqani, AS | 1 |
| Hamel, E | 3 |
| Lai, SW | 1 |
| Lin, HF | 1 |
| Lin, CL | 1 |
| Liao, KF | 1 |
| Nicolakakis, N | 2 |
| Aboulkassim, T | 2 |
| Ongali, B | 1 |
| Lecrux, C | 1 |
| Fernandes, P | 1 |
| Rosa-Neto, P | 2 |
| Tong, XK | 2 |
| Aliaga, A | 1 |
| Wang, CC | 1 |
| Chen, WL | 1 |
| Kao, TW | 1 |
| Chang, YW | 1 |
| Loh, CH | 1 |
| Chou, CC | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Brain; Cerebrovascular Disorders; Diabetes Mel | 2019 |
8 other studies available for pioglitazone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia.
Topics: Cerebrovascular Disorders; Dementia; Humans; Pioglitazone; Prediabetic State; Stroke | 2019 |
Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blood | 2017 |
Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan.
Topics: Aged; Case-Control Studies; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2016 |
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord | 2011 |
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; C | 2011 |